This study examined the effects of an invasive strategy, including coronary angiography and subsequent revascularization, compared to a conservative approach for older adults (≥75 years) experiencing non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS). The meta-analysis of nine studies indicated that invasive strategies significantly reduced the risk of death or myocardial infarction, myocardial infarction, and subsequent revascularization without increasing the risk of major bleeding. Despite limitations, the results highlight the potential benefits of invasive strategies for older adults with NSTE‐ACS, underscoring the need for future trials to further explore the nuances of geriatric conditions and to better represent the growing older adult population.

This is a research article describing a randomized trial comparing two different strategies for vascular access closure after transfemoral transcatheter aortic valve implantation (TF-TAVI), a procedure used to treat patients with severe aortic valve stenosis. The primary endpoint of the study was a composite of major or minor access site-related vascular complications during index hospitalization, with the study demonstrating that a combined suture-/plug-based vascular closure device (VCD) strategy was significantly superior to a suture-based VCD strategy. The study also found that the combined strategy was associated with shorter time to hemostasis and a lower rate of bleeding events compared to the suture-only approach. The researchers conclude that the combined strategy represents a promising option for vascular access closure after TF-TAVI.

This research article investigates the impact of using a microaxial flow pump (mAFP) on renal outcomes in patients experiencing cardiogenic shock (CS) due to ST-segment elevation myocardial infarction (STEMI). The study, a secondary analysis of the DanGer Shock trial, found that mAFP use was associated with higher rates of acute kidney injury (AKI) and renal replacement therapy (RRT), despite leading to a lower mortality rate at 180 days. The authors identify various predictors of AKI in both treatment groups, including shock severity, bleeding events, and device-related complications specific to the mAFP group, such as suction events and high pump speeds. The article concludes that while mAFP use presents a risk of AKI and RRT, the mortality benefit associated with its use remains significant, and further research should focus on minimizing the risks of device-related complications.